Hospira won approval for the first U.S. generic version of Sanofi-Aventis SA’s big-selling Taxotere cancer drug, sending Hospira shares up 2 percent.
U.S. sales of Taxotere, an infused chemotherapy known generically as docetaxel, were $1.2 billion last year, according to Hospira. JPMorgan analyst Chris Schott said recently that U.S. approval of generic Taxotere was the most important near-term catalyst for Hospira’s shares. Get the full story »